July 11, 2014 10:55 AM ET

Biotechnology

Company Overview of Genta Incorporated

Company Overview

Genta Incorporated, a biopharmaceutical company, engages in the identification, development, and commercialization of novel drugs for the treatment of cancer and related diseases. Its products include Tesetaxel, a novel taxane compound that has completed Phase 2 trials in patients with advanced gastric cancer, breast cancer, bladder cancer, prostate cancer, and melanoma. The company is also developing G4544a, an orally bioavailable gallium-containing compound, which has completed a single-dose Phase 1 clinical study for the treatment of diseases associated with accelerated bone loss. In addition, it markets Ganite, an intravenous formulation of gallium nitrate to treat cancer-related hyperca...

200 Connell Drive

Berkeley Heights, NJ 07922

United States

Founded in 1988

21 Employees

Phone:

908-286-9800

Fax:

908-464-1701

Key Executives for Genta Incorporated

Genta Incorporated does not have any Key Executives recorded.

Genta Incorporated Key Developments

Genta Incorporated Receives Approval from the Drug Regulatory Authority of the People's Republic of China to Start Clinical Trials with tesetaxel

On July 30, 2012, Genta Incorporated announced that it has received formal notice from the drug regulatory authority of the People's Republic of China (SFDA) that the company has received approval to start clinical trials with tesetaxel, its lead clinical compound, in China. SFDA has requested and approved a dose-ranging study of the combination of capecitabine plus tesetaxel, up to and including the dose used in a pivotal randomized trial (known as TESEGAST), as well as subsequent participation by China in the TESEGAST study. The TESEGAST study is designed to evaluate the safety and activity of tesetaxel plus capecitabine compared with capecitabine plus placebo in patients with advanced gastric cancer. Gastric cancer is the second most common tumor type in China.

Genta Incorporated Restates Earnings Results for the First Quarter Ended March 31, 2012

Genta Incorporated restated earnings results for the first quarter ended March 31, 2012. For the period, the company restated net loss was $10,664,000 or $0.01 basic and diluted per share against net income of $5,234,000 as reported.

Genta Incorporated to Report Q2, 2012 Results on Aug 13, 2012

Genta Incorporated announced that they will report Q2, 2012 results on Aug 13, 2012

Similar Private Companies By Industry

Company Name Region
Allergan Specialty Therapeutics, Inc. United States
Layton BioScience United States
Profectus Biosciences, Inc. United States
Vascular Magnetics, Inc. United States
Stem Cell Innovations, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 26, 2013
Genta Incorporated, Substantially All Assets
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genta Incorporated, please visit www.genta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.